Effects of endotoxin-induced fever and probenecid on disposition of enrofloxacin and its metabolite ciprofloxacin after intravascular administration of enrofloxacin in goats.
Pharmacokinetics of enrofloxacin and its active metabolite ciprofloxacin were investigated in normal, febrile and probenecid-treated adult goats after single intravenous (i.v.) administration of enrofloxacin (5 mg/kg). Pharmacokinetic evaluation of the plasma concentration-time data of enrofloxacin and ciprofloxacin was performed using two- and one-compartment open models, respectively. Plasma enrofloxacin concentrations were significantly higher in febrile (0.75-7 h) and probenecid-treated (5-7 h) goats than in normal goats. The sum of enrofloxacin and ciprofloxacin concentrations in plasma > or =0.1 microg /mL was maintained up to 7 and 8 h in normal and febrile or probenecid-treated goats, respectively. The t1/2beta, AUC, MRT and ClB of enrofloxacin in normal animals were determined to be 1.14 h, 6.71 microg .h/mL, 1.5 h and 807 mL/h/kg, respectively. The fraction of enrofloxacin metabolized to ciprofloxacin was 28.8%. The Cmax., t1/2beta, AUC and MRT of ciprofloxacin in normal goats were 0.45 microg /mL, 1.79 h, 1.84 microg .h/mL and 3.34 h, respectively. As compared with normal goats, the values of t1/2beta (1.83 h), AUC (11.68 microg ? h/mL) and MRT (2.13 h) of enrofloxacin were significantly higher, whereas its ClB (430 mL/h/kg) and metabolite conversion to ciprofloxacin (8.5%) were lower in febrile goats. The Cmax. (0.18 microg /mL) and AUC (0.99 microg .h/mL) of ciprofloxacin were significantly decreased, whereas its t1/2beta (2.75 h) and MRT (4.58 h) were prolonged in febrile than in normal goats. Concomitant administration of probenecid (40 mg/kg, i.v.) with enrofloxacin did not significantly alter any of the pharmacokinetic variables of either enrofloxacin or ciprofloxacin in goats.
Rao
G S
GS
Division of Pharmacology and Toxicology, Indian Veterinary Research Institute, IZATNAGAR-243 122 (U.P.), India. hct55@ivri.up.nic.in
Ramesh
S
S
Ahmad
A H
AH
Tripathi
H C
HC
Sharma
L D
LD
Malik
J K
JK
D000818:Animals; D000890:Anti-Infective Agents / Q000097:blood / Q000493:pharmacokinetics*; D019540:Area Under Curve; D002939:Ciprofloxacin / Q000097:blood / Q000493:pharmacokinetics*; D004347:Drug Interactions; D004731:Endotoxins / Q000633:toxicity*; D000077422:Enrofloxacin; D005260:Female; D005334:Fever / Q000139:chemically induced / Q000378:metabolism*; D024841:Fluoroquinolones; D006041:Goats; D006207:Half-Life; D007275:Injections, Intravenous; D008657:Metabolic Clearance Rate; D011339:Probenecid / Q000633:toxicity*; D015363:Quinolones / Q000097:blood / Q000493:pharmacokinetics*; D014528:Uricosuric Agents / Q000633:toxicity*
D000890:Anti-Infective Agents; D004731:Endotoxins; D024841:Fluoroquinolones; D015363:Quinolones; D014528:Uricosuric Agents; D000077422:Enrofloxacin; D002939:Ciprofloxacin; D011339:Probenecid